Immunomodulatory treatment with mesenchymal stromal cells represents a novel therapeutic modality for immune-mediated kidney injury, including in the settings of renal transplantation and glomerulonephritis. A new study illustrates the complexity of aligning clinical trial design, manufacturing and availability of biomarkers in order to turn this promising concept into a therapeutic reality.
Refers to Deng, D. Q., Zhang, P., Guo, Y. & Lim, T. O. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann. Rheum. Dis.http://dx.doi.org/10.1136/annrheumdis-2017–211073 (2017)